Multiple genetic mutations and adaptations drive the formation of unique tumor microenvironments (TMEs), often resulting in the upregulation of tumor‐specific biomarkers.[163, 164, 165] Among these, SPARC stands out as a key target—it is highly overexpressed in many malignant tumors but minimally present in normal tissues, making it an ideal candidate for tumor‐specific drug delivery.[2, 166, 167, 168, 169] Capitalizing on SPARC's affinity for albumin, Chang et al. This evidence concerns the gene SPARC and neoplasm.